C4 Therapeutics (CCCC) Current Leases (2019 - 2026)

C4 Therapeutics has reported Current Leases for 8 years, with the latest figure at $6.5 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 10.19% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at $6.5 million (up 10.19% YoY), and the FY2025 full-year result was $6.4 million, up 10.27% from the prior year.
• Current Leases for Q1 2026 stood at $6.5 million, up from $6.4 million in the prior quarter.
• The five-year high for Current Leases was $6.5 million in Q1 2026, with the low at $1.7 million in Q1 2022.
• Average Current Leases over 5 years is $5.1 million, with a median of $5.4 million recorded in 2024.
• Year-over-year, Current Leases surged 288.87% in 2022 and gained 10.19% in 2026.
• Tracing CCCC's Current Leases over 5 years: stood at $4.7 million in 2022, then climbed by 11.04% to $5.2 million in 2023, then climbed by 10.63% to $5.8 million in 2024, then advanced by 10.27% to $6.4 million in 2025, then rose by 2.43% to $6.5 million in 2026.
• The last three Current Leases figures came in at $6.5 million (Q1 2026), $6.4 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.

Peer Comparison